What question did this study set out to answer?

March 7, 2026Open Access

Haploidentical Hematopoietic Stem Cell Transplantation With Anti-Thymocyte Globulin in the Treatment of Older Adults With Hematological Malignancy.

Puntos clave

The central aim is to evaluate the safety and efficacy of haploidentical hematopoietic stem cell transplantation with anti-thymocyte globulin in older adults.
Conducted a trial evaluating treatment outcomes in patients aged 60 and older.
Administered haploidentical stem cell transplantation with anti-thymocyte globulin.
Monitored safety and efficacy outcomes over a determined follow-up period.
Haploidentical SCT with ATG is found to be safe for patients aged ≥ 60 years.
The treatment shows promising efficacy in managing hematological malignancies.

Resumen

Our study suggests that haplo-SCT with ATG is a safe and effective treatment option for patients aged ≥ 60 years. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo